Edition:
United States

Endologix Inc (ELGX.OQ)

ELGX.OQ on NASDAQ Stock Exchange Global Select Market

7.06USD
1:57pm EDT
Change (% chg)

$-0.00 (-0.07%)
Prev Close
$7.07
Open
$7.07
Day's High
$7.08
Day's Low
$6.92
Volume
82,060
Avg. Vol
464,394
52-wk High
$14.49
52-wk Low
$4.79

Latest Key Developments (Source: Significant Developments)

Brown Capital reports a 10.58 pct passive stake in Endologix Inc
Tuesday, 7 Mar 2017 10:11am EST 

Endologix Inc :Brown Capital Management LLC reports a 10.58 percent passive stake in Endologix Inc as of Feb 28, 2017.  Full Article

Endologix reports Q4 loss per share of $0.30
Wednesday, 22 Feb 2017 04:05pm EST 

Endologix Inc : Endologix reports results for the fourth quarter and full year 2016 . Sees FY 2017 GAAP loss per share $0.70 to $0.76 . Q4 loss per share $0.30 . Sees FY 2017 revenue $193 million to $200 million . Sees FY 2017 revenue up 0 to 4 percent . Q4 revenue $47.5 million versus I/B/E/S view $48.7 million . Q4 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S .FY2017 earnings per share view $-0.70, revenue view $199.5 million -- Thomson Reuters I/B/E/S.  Full Article

Endologix appoints Dan Lemaitre as chairman of board
Monday, 6 Feb 2017 09:00am EST 

Endologix Inc : Endologix announces appointment of Dan Lemaitre as chairman of the board . Says Dan Lemaitre appointed chairman of the board . Endologix Inc - Dan Lemaitre, lead independent director, has been appointed chairman, and John Mcdermott, will continue to serve as CEO .Endologix Inc - board of directors has elected to separate positions of chairman of board and chief executive officer, effective today.  Full Article

ENDOLOGIX SAYS CE MARK FOR AFX AND AFX2 ENDOVASCULAR AAA SYSTEMS HAS BEEN REINSTATED
Wednesday, 25 Jan 2017 12:00pm EST 

Endologix Inc : RECEIVED NOTICE FROM ITS NOTIFIED BODY IN EUROPEAN UNION THAT CE MARK FOR AFX® AND AFX2 ENDOVASCULAR AAA SYSTEMS HAS BEEN REINSTATED .CE MARK WAS REINSTATED BASED UPON LOW RATES OF REPORTED TYPE III ENDOLEAKS WITH CURRENT GENERATION OF AFX PRODUCTS.  Full Article

Endologix provides physicians with updated information about the afx® endovascular aaa system
Friday, 30 Dec 2016 08:00am EST 

Endologix Inc : Endologix - letter with guidance for physicians includes a voluntary recall of limited number of first-generation afx devices remaining in inventories . Endologix - released all sizes of afx and some sizes of afx2 from hold, and developed a plan to release remaining sizes of afx2 as soon as possible . Endologix - letter with guidance for physicians also includes voluntary recall of some sizes of afx2 related to co-issued product hold . Endologix Inc - "to date, reported rates of type iii endoleaks with current version of afx (with duraply) and afx2 are very low" .Endologix provides physicians with updated information about the afx® endovascular aaa system.  Full Article

Endologix announces temporary hold on AFX to resolve a manufacturing issue
Tuesday, 27 Dec 2016 07:30am EST 

Endologix Inc : Endologix announces temporary hold on AFX to resolve a manufacturing issue . Company expects temporary hold to be lifted for some sizes in near future . AFX manufacturing issue is unrelated to manufacturing process for Nellix and Ovation, which continue to be available in approved markets . Temporary hold on AFX is not related to any reported events from physicians ."continue to see very good commercial clinical results with latest versions of AFX and AFX2".  Full Article

Endologix provides update on Nellix PMA process
Wednesday, 16 Nov 2016 09:00am EST 

Endologix Inc : Endologix provides update on Nellix PMA process . Endologix Inc says expects data to be available and submitted to FDA in Q2 of 2017 . Endologix - FDA requested company provide 2-year patient follow-up data from EVAS-FORWARD IDE study of Nellix endovascular aneurysm sealing system .Expects a possible FDA advisory panel meeting by end of 2017, and potential FDA PMA approval of Nellix in Q2 of 2018.  Full Article

Endologix announces first patients treated with Ovation Alto Abdominal Stent Graft System
Wednesday, 17 Aug 2016 09:00am EDT 

Endologix Inc : Endologix announces first patients treated with Ovation Alto™ Abdominal Stent Graft System .Ovation alto expected to be introduced into Europe in 2017 and U.S. In 2018.  Full Article

Endologix reports results for the second quarter 2016
Tuesday, 2 Aug 2016 04:05pm EDT 

Endologix Inc : Sees FY 2016 GAAP loss per share $1.80 to $1.85 . Sees FY 2016 revenue $197 million to $203 million . Q2 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S . Endologix reports results for the second quarter 2016 . Q2 loss per share $0.81 . Q2 revenue $51 million versus I/B/E/S view $46.3 million . Sees FY 2016 adjusted non-GAAP loss per share $0.70 to $0.75 .FY2016 earnings per share view $-0.79, revenue view $198.2 million -- Thomson Reuters I/B/E/S.  Full Article

Brown Capital Management LLC reports 5.93 pct passive stake in Endologix - SEC filing
Thursday, 7 Jul 2016 12:50pm EDT 

Brown Capital Management LLC:Brown Capital Management, LLC reports 5.93 percent passive stake in Endologix Inc as of June 30 - SEC filing.  Full Article

More From Around the Web

BRIEF-Brown Capital reports a 10.58 pct passive stake in Endologix Inc

* Brown Capital Management LLC reports a 10.58 percent passive stake in Endologix Inc as of Feb 28, 2017 Source text:(http://bit.ly/2miclCd) Further company coverage: